1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
PD‐L1 Expression in Non‐Small Cell Lung Cancer Specimens : Association with Clinicopathological Factors and Molecular Alterations
(
- Contribution to journal › Article
- 2021
-
Mark
Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations
(
- Contribution to journal › Article
- 2019
-
Mark
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
(
- Contribution to journal › Article
-
Mark
Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
(
- Contribution to journal › Article
- 2018
-
Mark
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
(
- Contribution to journal › Article
- 2013
-
Mark
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.
(
- Contribution to journal › Article
- 2001
-
Mark
Molecular Genetic Alterations In Endometrial And Ovarian Cancers
2001)(
- Thesis › Doctoral thesis (compilation)